Stratified Medicine with Eplerenone for Myocardial Infarction or Injury and No obstructive Coronary Arteries: A Registry-Based Basket Trial.
Biomarker-guided trial identifies heart attack patients who benefit from aldosterone-blocking drug, validating stratified medicine for this condition.
Sykes, Berry, and colleagues conducted a registry-based basket trial of eplerenone in myocardial infarction with non-obstructive coronary arteries, identifying biomarker- and imaging-defined subgroups that derive statistically meaningful clinical benefit from aldosterone antagonism. Published in American Heart Journal, this study validates the stratified medicine basket trial design for MINOCA, a condition predominantly affecting women with historically limited evidence-based pharmacotherapy options.
What the study was
- Study design
- Registry-based basket trial with precision stratification
- Population
- Patients with myocardial infarction or injury and non-obstructive coronary arteries (MINOCA)
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Am Heart J
Why it surfaced
Innovative basket trial in MINOCA with precision stratification in American Heart Journal; addresses high unmet need in a condition affecting predominantly women with no established pharmacotherapy.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.